Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex most commonly
associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first described it in …

Abstract Background & Aims Pancreatic ductal adenocarcinoma (PDAC) incidence is rising
worldwide, and most patients present with an unresectable disease at initial diagnosis …

CA 19-9 and CEA are the most commonly used biomarkers for diagnosis and management
of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990 …

A label-free electrochemical immunosensor was successfully developed for sensitively
detecting carbohydrate antigen 19–9 (CA19-9) as a cancer marker. To achieve this, a series …

Objective: Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with
pancreatic cancer (PC), but its value as a treatment biomarker is unclear. Summary …

Purpose In pancreatic cancer, genetic markers to aid clinical decision making are still
lacking. The present study was designed to determine the prognostic role of perioperative …

Liquid biopsy, which is a minimally invasive procedure as an alternative to tissue biopsy,
has been introduced as a new diagnostic/prognostic measure. By screening disease-related …

Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical
resection is a requirement for a potential cure. However, the majority of patients are …